Ethacrynic Acid
FDA-approved product (tablet, oral), marketed as Edecrin, Ethacrynate Sodium, Ethacrynic Acid.
- Registered studies
- 0
- Lab records
- 1
- Pathogens at ≥40%
- 1 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Cardiovascular disease
- Cirrhosis of liver
- Congestive heart failure
- Nephrotic syndrome
- Pulmonary edema
- Urinary system disease
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Aryloxyacetic acid derivatives
- FDA pharmacologic class
- Loop Diuretic FDA label ↗
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.
AI-predicted activity
AI prediction · nothing measured- MRSA26.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
- E. coli23.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae17.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis50.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
No evidence found
The registry was searched and no registered study names this medicine.
Experimental
- MRSA: measured active in 0 of 1 lab record
Show the 1 laboratory record, with sources
Loading records…
“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Ethacrynic Acid with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Lumateperone TosylateExisting use: Psychosis, Schizophrenia65.8% AI-predicted activityagainst M. tuberculosis6 registered studies
- Moexipril HydrochlorideExisting use: Cardiovascular disease, Hypertension65.8% AI-predicted activityagainst M. tuberculosis12 registered studies
- VismodegibExisting use: Basal cell carcinoma, Cancer, Neoplasm and 1 more65.8% AI-predicted activityagainst M. tuberculosis50+ registered studies
- DarunavirExisting use: HIV infection, HIV-1 infection, Immunodeficiency disease and 2 more65.6% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Lenacapavir SodiumExisting use: HIV infection, HIV-1 infection, Viral disease65.6% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- LisinoprilExisting use: Cardiovascular disease, Congestive heart failure, Diabetes mellitus and 4 more65.6% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Umbralisib TosylateExisting use: Follicular lymphoma, Marginal zone B-cell lymphoma, Neoplasm65.6% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- BrigatinibExisting use: Neoplasm, Non-small cell lung carcinoma65.4% AI-predicted activityagainst M. tuberculosis48 registered studies
- GlyburideExisting use: Diabetes mellitus, Type 2 diabetes mellitus65.4% AI-predicted activityagainst M. tuberculosis50+ registered studies
- ThiothixeneExisting use: Psychosis, Schizophrenia65.4% AI-predicted activityagainst M. tuberculosis5 registered studies
- GefitinibExisting use: Cancer, Neoplasm, Non-small cell lung carcinoma65.4% AI-predicted activityagainst M. tuberculosis50+ registered studies
- PimozideExisting use: Psychosis, Tics, Tourette syndrome65.2% AI-predicted activityagainst M. tuberculosis15 registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
No evidence found: the registry was searched and no registered study names this medicine.